The Experts below are selected from a list of 1395 Experts worldwide ranked by ideXlab platform
Charles R. Taylor - One of the best experts on this subject based on the ideXlab platform.
-
broad band uvb fiber optic comb for the treatment of Scalp Psoriasis a pilot study
International Journal of Dermatology, 2004Co-Authors: Atul K Taneja, A Racette, Zafirios Gourgouliatos, Charles R. TaylorAbstract:Background Scalp Psoriasis is a frustrating condition with limited treatment options. Our objective was to test a new fiber-optic broad-band UVB comb device for the treatment of this condition. Methods Scalp Psoriasis on adult subjects was treated three times a week for up to 12 weeks with a fiber-optic UVB comb. A minimum 50-cm2 Scalp area served as the control. Starting doses were based on the standard minimal erythema dose (MED) with increments up to 20% for subsequent treatments. Results Fourteen subjects completed the study without sunburn reactions or blisters. Treated sites showed a mean improvement in the modified PASI score of 3.6. The difference in the mean modified PASI scores between the control and treated sites was 3.9 (< 0.0001). Conclusions This fiber-optic broad-band UVB comb can safely and effectively treat Scalp Psoriasis.
-
308-nm excimer laser for the treatment of Scalp Psoriasis.
Archives of Dermatology, 2004Co-Authors: Samir N. Gupta, Charles R. TaylorAbstract:A 49-year-old white woman presented with a 20-year history of Scalp Psoriasis. Over the years, she had tried numerous topical treatments, such as 0.05% clobetasol propionate solution with 0.005% calcipotriene solution for 3 months, as well as various tar- and salicylic acid– based shampoos, with no success. She stated that the itching associated with her Scalp Psoriasis had worsened over the past year, often keeping her awake at night. She had abandoned medical treatment for 6 months. She was otherwise in good health and was not taking any medications. There was no family history of skin disease. Physical examination revealed thick, hyperkeratotic, scaly, erythematous, confluent plaques almost completely covering the Scalp, including the postauricular area, clinically consistent with Scalp Psoriasis.
-
a 308 nm excimer laser for the treatment of Scalp Psoriasis
Lasers in Surgery and Medicine, 2004Co-Authors: Charles R. Taylor, A RacetteAbstract:Background and Objectives Scalp Psoriasis is a frustrating disorder whose treatments can all too often be cumbersome and ineffective. Our objective was to test a combination device involving the 308-nm excimer laser in tandem with a hair blower for treating Scalp Psoriasis. Study Design/Materials and Methods Adult subjects with Scalp Psoriasis unresponsive to class I topical steroids used in conjunction with medicated shampoos were treated with 308-nm excimer laser pulses in conjunction with a hair blower that parted the obstructing hair twice a week for up to 15 weeks. Half of the Scalp served as a control. Starting doses were based on standard minimal erythema dose (MED)'s with subsequent increments of up to 20%. Results Thirteen subjects completed the study without adverse events. Two were dropped due to lack of compliance. At the end of the investigation, the difference in the mean modified PASI scores between the control and treated sites was 4.0 (<0.0001). Conclusions The air blower device in conjunction with the 308-nm excimer laser can safely and effectively treat otherwise refractory Scalp Psoriasis. Lasers Surg. Med. 34:136–140, 2004. © 2004 Wiley-Liss, Inc.
-
A 308‐nm excimer laser for the treatment of Scalp Psoriasis
Lasers in Surgery and Medicine, 2004Co-Authors: Charles R. Taylor, A RacetteAbstract:Background and Objectives Scalp Psoriasis is a frustrating disorder whose treatments can all too often be cumbersome and ineffective. Our objective was to test a combination device involving the 308-nm excimer laser in tandem with a hair blower for treating Scalp Psoriasis. Study Design/Materials and Methods Adult subjects with Scalp Psoriasis unresponsive to class I topical steroids used in conjunction with medicated shampoos were treated with 308-nm excimer laser pulses in conjunction with a hair blower that parted the obstructing hair twice a week for up to 15 weeks. Half of the Scalp served as a control. Starting doses were based on standard minimal erythema dose (MED)'s with subsequent increments of up to 20%. Results Thirteen subjects completed the study without adverse events. Two were dropped due to lack of compliance. At the end of the investigation, the difference in the mean modified PASI scores between the control and treated sites was 4.0 (
-
Broad-band UVB fiber-optic comb for the treatment of Scalp Psoriasis: a pilot study
International Journal of Dermatology, 2004Co-Authors: Atul K Taneja, A Racette, Zafirios Gourgouliatos, Charles R. TaylorAbstract:Background Scalp Psoriasis is a frustrating condition with limited treatment options. Our objective was to test a new fiber-optic broad-band UVB comb device for the treatment of this condition. Methods Scalp Psoriasis on adult subjects was treated three times a week for up to 12 weeks with a fiber-optic UVB comb. A minimum 50-cm2 Scalp area served as the control. Starting doses were based on the standard minimal erythema dose (MED) with increments up to 20% for subsequent treatments. Results Fourteen subjects completed the study without sunburn reactions or blisters. Treated sites showed a mean improvement in the modified PASI score of 3.6. The difference in the mean modified PASI scores between the control and treated sites was 3.9 (
A Racette - One of the best experts on this subject based on the ideXlab platform.
-
broad band uvb fiber optic comb for the treatment of Scalp Psoriasis a pilot study
International Journal of Dermatology, 2004Co-Authors: Atul K Taneja, A Racette, Zafirios Gourgouliatos, Charles R. TaylorAbstract:Background Scalp Psoriasis is a frustrating condition with limited treatment options. Our objective was to test a new fiber-optic broad-band UVB comb device for the treatment of this condition. Methods Scalp Psoriasis on adult subjects was treated three times a week for up to 12 weeks with a fiber-optic UVB comb. A minimum 50-cm2 Scalp area served as the control. Starting doses were based on the standard minimal erythema dose (MED) with increments up to 20% for subsequent treatments. Results Fourteen subjects completed the study without sunburn reactions or blisters. Treated sites showed a mean improvement in the modified PASI score of 3.6. The difference in the mean modified PASI scores between the control and treated sites was 3.9 (< 0.0001). Conclusions This fiber-optic broad-band UVB comb can safely and effectively treat Scalp Psoriasis.
-
a 308 nm excimer laser for the treatment of Scalp Psoriasis
Lasers in Surgery and Medicine, 2004Co-Authors: Charles R. Taylor, A RacetteAbstract:Background and Objectives Scalp Psoriasis is a frustrating disorder whose treatments can all too often be cumbersome and ineffective. Our objective was to test a combination device involving the 308-nm excimer laser in tandem with a hair blower for treating Scalp Psoriasis. Study Design/Materials and Methods Adult subjects with Scalp Psoriasis unresponsive to class I topical steroids used in conjunction with medicated shampoos were treated with 308-nm excimer laser pulses in conjunction with a hair blower that parted the obstructing hair twice a week for up to 15 weeks. Half of the Scalp served as a control. Starting doses were based on standard minimal erythema dose (MED)'s with subsequent increments of up to 20%. Results Thirteen subjects completed the study without adverse events. Two were dropped due to lack of compliance. At the end of the investigation, the difference in the mean modified PASI scores between the control and treated sites was 4.0 (<0.0001). Conclusions The air blower device in conjunction with the 308-nm excimer laser can safely and effectively treat otherwise refractory Scalp Psoriasis. Lasers Surg. Med. 34:136–140, 2004. © 2004 Wiley-Liss, Inc.
-
A 308‐nm excimer laser for the treatment of Scalp Psoriasis
Lasers in Surgery and Medicine, 2004Co-Authors: Charles R. Taylor, A RacetteAbstract:Background and Objectives Scalp Psoriasis is a frustrating disorder whose treatments can all too often be cumbersome and ineffective. Our objective was to test a combination device involving the 308-nm excimer laser in tandem with a hair blower for treating Scalp Psoriasis. Study Design/Materials and Methods Adult subjects with Scalp Psoriasis unresponsive to class I topical steroids used in conjunction with medicated shampoos were treated with 308-nm excimer laser pulses in conjunction with a hair blower that parted the obstructing hair twice a week for up to 15 weeks. Half of the Scalp served as a control. Starting doses were based on standard minimal erythema dose (MED)'s with subsequent increments of up to 20%. Results Thirteen subjects completed the study without adverse events. Two were dropped due to lack of compliance. At the end of the investigation, the difference in the mean modified PASI scores between the control and treated sites was 4.0 (
-
Broad-band UVB fiber-optic comb for the treatment of Scalp Psoriasis: a pilot study
International Journal of Dermatology, 2004Co-Authors: Atul K Taneja, A Racette, Zafirios Gourgouliatos, Charles R. TaylorAbstract:Background Scalp Psoriasis is a frustrating condition with limited treatment options. Our objective was to test a new fiber-optic broad-band UVB comb device for the treatment of this condition. Methods Scalp Psoriasis on adult subjects was treated three times a week for up to 12 weeks with a fiber-optic UVB comb. A minimum 50-cm2 Scalp area served as the control. Starting doses were based on the standard minimal erythema dose (MED) with increments up to 20% for subsequent treatments. Results Fourteen subjects completed the study without sunburn reactions or blisters. Treated sites showed a mean improvement in the modified PASI score of 3.6. The difference in the mean modified PASI scores between the control and treated sites was 3.9 (
-
021 UVB emitting fiber optic hair brush for the treatment of Scalp Psoriasis
Photodermatology Photoimmunology & Photomedicine, 2002Co-Authors: Atul K Taneja, A Racette, Zafirios Gourgouliatos, Manju Trehan, S. Gupta, S. Regan, Charles R. TaylorAbstract:This work-in-progress evaluates the efficacy of a unique UVB fiber optic comb device for treating Scalp Psoriasis. Informed consent was obtained on 11 enrolled patients. One Scalp Psoriasis plaque was left as a control, while another was selected for treatment. An MED was performed on the lower back or gluteal skin to determine the subject's baseline sensitivity to the comb device. On the selected sit, mineral oil was first applied with a soaked gauze to enhance UV delivery and the first treatment was at 1 MED. Subsequent treatments were thrice weekly at 72 h intervals with maximum increments of 20% per treatment. Treatments ended after 12 weeks or when clearing occurred, whichever came first. Clinical evaluation and standardized photographs were taken at baseline and every 2 weeks thereafter. Results On average, patients have received 24 treatments (range: 2–36). At baseline, PASI scores for the treated and control sides did not differ significantly (mean difference: 0.4, P= 0.1106). Improvement scores, calculated by subtracting the most recent PASI score from the baseline value, were higher for the treated sides (3.9 vs. 0.3, P = 0.0002). Three patients showed worsening in the control area. Ten of the 11 patients showed improvement in the treated area; none experienced worsening of symptoms. Conclusions The fiber optic brush offers an exciting potential for treating Scalp Psoriasis.
Christopher E. M. Griffiths - One of the best experts on this subject based on the ideXlab platform.
-
Topical Treatments for Scalp Psoriasis
Drugs, 2008Co-Authors: Richard B. Warren, Benjamin C. Brown, Christopher E. M. GriffithsAbstract:Psoriasis is a common, chronic inflammatory skin disease that affects the Scalp more commonly than any other site. Scalp Psoriasis causes significant psychosocial disability as it is highly visible and can, on occasion, extend onto the face. Furthermore, current treatment regimens are messy, time consuming and, in some instances, ineffective, leading to a high level of non-compliance. The majority of current evidence for topical treatments for this condition comes from open-label, uncontrolled studies. From such studies, there are data to support the use of topical corticosteroids in a number of different formulations and topical vitamin D analogues. However, these studies have not addressed issues such as the need for keratolytics, which may be required to remove adherent scale before a topical corticosteroid or vitamin D analogue may prove efficacious. There is an urgent need for well designed, controlled trials to assess the efficacy of existing and new treatment regimens for Scalp Psoriasis. The aim of this review is to critically assess the relative effectiveness and tolerability of available topical therapies for this problematic condition and provide recommendations for selection of treatment.
Leon Kircik - One of the best experts on this subject based on the ideXlab platform.
-
Salicylic Acid 6% in an Ammonium Lactate Emollient Foam Vehicle in the Treatment of Mild-to-Moderate Scalp Psoriasis
J Drugs Dermatol, 2011Co-Authors: Leon KircikAbstract:Scalp Psoriasis is a common life-al tering skin condition causing a great deal of distress. It significantly affects quality of life and is difficult to manage. Treatment can provide variable results, often impacting patient compliance with therapy. Salicylic acid is used as adjunctive therapy to other topical treatments because of its marked keratolytic effect. Its effectiveness as a monotherapy is not fully understood. An emollient foam formulation of 6% salicylic acid (Salkera) in an ammonium lactate vehicle has recently become available. Efficacy, tolerability and patient acceptability of salicylic acid 6% emollient foam were assessed in an open-label pilot study of 10 subjects with Scalp Psoriasis. All Psoriasis severity parameters were reduced with a significant decrease in Psoriasis Scalp Severity Index (PSSI) score from 15.3 to 3.0 after four weeks of monotherapy (P
Tsen-fang Tsai - One of the best experts on this subject based on the ideXlab platform.
-
Managing Scalp Psoriasis: An Evidence-Based Review
American Journal of Clinical Dermatology, 2017Co-Authors: Ting-shun Wang, Tsen-fang TsaiAbstract:Background Scalp Psoriasis is commonly the initial presentation of Psoriasis, and almost 80 % of patients with Psoriasis will eventually experience it. Objective Although several systematic reviews and guidelines exist, an up-to-date evidence-based review including more recent progress on the use of biologics and new oral small molecules was timely. Methods Of the 475 studies initially retrieved from PubMed and the 845 from Embase (up to May 2016), this review includes 27 clinical trials, four papers reporting pooled analyses of other clinical trials, ten open-label trials, one case series, and two case reports after excluding non-English literature. Results To our knowledge, few randomized controlled trials (RCTs) are conducted specifically in Scalp Psoriasis. Topical corticosteroids provide good effects and are usually recommended as first-line treatment. Calcipotriol–betamethasone dipropionate is well tolerated and more effective than either of its individual components. Localized phototherapy is better than generalized phototherapy on hair-bearing areas. Methotrexate, cyclosporine, fumaric acid esters, and acitretin are well-recognized agents in the treatment of Psoriasis, but we found no published RCTs evaluating these agents specifically in Scalp Psoriasis. Biologics and new small-molecule agents show excellent effects on Scalp Psoriasis, but the high cost of these treatments mean they may be limited to use in extensive Scalp Psoriasis. Conclusions More controlled studies are needed for an evidence-based approach to Scalp Psoriasis.
-
Managing Scalp Psoriasis: An Evidence-Based Review.
American Journal of Clinical Dermatology, 2016Co-Authors: Ting-shun Wang, Tsen-fang TsaiAbstract:Scalp Psoriasis is commonly the initial presentation of Psoriasis, and almost 80 % of patients with Psoriasis will eventually experience it. Although several systematic reviews and guidelines exist, an up-to-date evidence-based review including more recent progress on the use of biologics and new oral small molecules was timely. Of the 475 studies initially retrieved from PubMed and the 845 from Embase (up to May 2016), this review includes 27 clinical trials, four papers reporting pooled analyses of other clinical trials, ten open-label trials, one case series, and two case reports after excluding non-English literature. To our knowledge, few randomized controlled trials (RCTs) are conducted specifically in Scalp Psoriasis. Topical corticosteroids provide good effects and are usually recommended as first-line treatment. Calcipotriol–betamethasone dipropionate is well tolerated and more effective than either of its individual components. Localized phototherapy is better than generalized phototherapy on hair-bearing areas. Methotrexate, cyclosporine, fumaric acid esters, and acitretin are well-recognized agents in the treatment of Psoriasis, but we found no published RCTs evaluating these agents specifically in Scalp Psoriasis. Biologics and new small-molecule agents show excellent effects on Scalp Psoriasis, but the high cost of these treatments mean they may be limited to use in extensive Scalp Psoriasis. More controlled studies are needed for an evidence-based approach to Scalp Psoriasis.
-
recommendations for a patient centered approach to the assessment and treatment of Scalp Psoriasis a consensus statement from the asia Scalp Psoriasis study group
Journal of Dermatological Treatment, 2014Co-Authors: Maria Lorna F. Frez, Tsen-fang Tsai, Pravit Asawanonda, Chalukya Gunasekara, Chuankeng Koh, Steven Loo, Hazel H Oon, Vu Hong Thai, Sang Woong YounAbstract:Background: International consensus statements on the management of Scalp Psoriasis are available, but no such recommendations exist for Asia. Methods: The Asia Scalp Psoriasis Study Group (ASPSG) met in May 2011 to review the epidemiologic pattern of Scalp Psoriasis in Southeast Asia and to develop Asia-specific recommendations for its management. Results: The overall prevalence of Psoriasis in Asia is <0.3%, but 75–90% have Scalp involvement, whether isolated or with lesions elsewhere, which can negatively impact quality of life (QoL). Treatment decisions should be based primarily on objective disease severity, but should also take account of patient QoL. Psychosocial support and more aggressive treatment should be offered to all patients with moderate to severe QoL impairment. Topical therapy is indicated first-line in all patients, with combination therapy (corticosteroid + calcipotriol), more occlusive formulations, keratolytics, and very potent corticosteroids for patients needing greater or faster ...
-
Recommendations for a patient-centered approach to the assessment and treatment of Scalp Psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group
Journal of Dermatological Treatment, 2013Co-Authors: Maria Lorna F. Frez, Tsen-fang Tsai, Pravit Asawanonda, Chalukya Gunasekara, Chuankeng Koh, Steven Loo, Hazel H Oon, Vu Hong Thai, Sang Woong YounAbstract:Background: International consensus statements on the management of Scalp Psoriasis are available, but no such recommendations exist for Asia. Methods: The Asia Scalp Psoriasis Study Group (ASPSG) met in May 2011 to review the epidemiologic pattern of Scalp Psoriasis in Southeast Asia and to develop Asia-specific recommendations for its management. Results: The overall prevalence of Psoriasis in Asia is
